This study could significantly impact Regeneron and Intellia’s stock performance by showcasing their innovative approach to gene therapy. Success in this study may enhance investor sentiment and ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD due to inspection findings at a Catalent manufacturing site, despite ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...